Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

61.95 -0.29 (-0.47%)
Streaming Delayed Price Updated: 9:33 AM EDT, May 17, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 237,552
Open 62.42
Bid (Size) 61.95 (2)
Ask (Size) 61.98 (1)
Prev. Close 62.24
Today's Range 61.95 - 62.49
52wk Range 57.19 - 74.12
Shares Outstanding 1,253,809,440
Dividend Yield 4.58%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The Daily Biotech Pulse: Pfizer-BioNTech's COVID-19 Booster For Kids 5-11 Coming Soon, Ultragenyx In-Licenses Gene Therapy For Genetic Disorder, Ampio's AP-013 Trial Under Independent Investigation
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
FDA Lifts Clinical Hold on Investigational Lenacapavir for the Treatment and Prevention of HIV
From Gilead Sciences, Inc.
Via Business Wire

Performance

YTD
-14.65%
-14.65%
1 Month
+0.60%
+0.60%
3 Month
+1.37%
+1.37%
6 Month
-7.81%
-7.81%
1 Year
-10.31%
-10.31%

More News

Read More
This Dirt-Cheap Stock Looks Attractive And Pays A Market-Smashing Yield
Via Talk Markets
Why These Analysts Are Bullish On Gilead's Q1 Earnings
Via Benzinga
Gilead Sciences Crushes First-Quarter Views As Covid Drug Adds $1.5 Billion
Via Investor's Business Daily
Recap: Gilead Sciences Q1 Earnings
Via Benzinga
Large Cap Biopharmaceuticals: Provide Growth, Value And Yield
Via Talk Markets
Stocks Are Undervalued
Via Talk Markets
Playwright Lee Raines Shines a Spotlight on the Criminalization of HIV
Via 3BL Media
Crispr Therapeutics Rallies As It Plots Out Its Next Cancer Move Vs. Gilead, Novartis
Via Investor's Business Daily
Why Roche's Flop In Lung Cancer Hammered Arcus, Iteos And Others
Via Investor's Business Daily
Gilead Sciences Presents at ECCMID 2022 - Continues Mission to Advance Access to Effective Therapies
Via 3BL Media
Arcus Posts Encouraging Data For Domvanalimab-Based Regimes In Lung Cancer Settings
Via Benzinga
RBC Expects Business Development To Unlock This Pharma Stock's Balance Sheet Value
Via Benzinga
Closing the Representation Gap in Schools, One Black Male Teacher at a Time
Via 3BL Media
Topics Product Recall
Exposures Legal Product Safety
Pfizer: The Treasure of Albert Bourla
Via InvestorPlace
May 2022 Stock Considerations
Via Talk Markets
Opinion: The Road to Ending Visceral Leishmaniasis
Via 3BL Media
Bio-based Platform Chemicals Market Size Estimated to Reach US$26.3 billion by 2027
Via iCrowdNewswire
Topics Derivatives
Exposures COVID-19 Derivatives
Gilead and Dragonfly Announce Strategic Research Collaboration to Develop Natural Killer Cell Engagers in Oncology and Inflammation
From Gilead Sciences, Inc.
Via Business Wire
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much
Via Benzinga
On Earth Day, Gilead Marks Strides in Environmental Sustainability
Via 3BL Media
Topics Emissions
Gilead Sciences Q1 Results Surpass Street Expectation, FY22 Outlook Midpoint Trails Consensus
Via Benzinga
Gilead Sciences Announces First Quarter 2022 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
The Daily Biotech Pulse: Moderna Seeks FDA Approval For COVID-19 Shot For Children 2-6, Tax Disclosure For Amgen, Fast Track Tags For SQZ Biotech, Timber Pharma Candidates
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.